| 1. A method to reduce the exocytotic MARCKS-related release of at least one inflammatory mediator from at least one inflammatory
cell comprising contacting the inflammatory cell, which cell comprises the inflammatory mediator contained within a granule
inside the cell, with at least one peptide selected from the group consisting of a MANS peptide and an active fragment thereof,
wherein said fragment comprises at least six amino acids, in an effective amount to reduce the release of the inflammatory
mediator from the inflammatory cell as compared to the release of the inflammatory mediator from the same type of inflammatory
cell that would occur in the absence of the peptide,
wherein said inflammatory mediator is selected from the group consisting of myeloperoxidase (MPO), eosinophil peroxidase (EPO),
major basic protein (MBP), lysozyme, granzyme, histamine, proteoglycan, protease, cytokine, defensin, bactericidal permeability-increasing
protein (BPI), elastase, cathepsin G, cathepsin B, cathepsin D, beta-D-glucuronidase, alpha-mannosidase, phospholipase A2, chondroitin-4-sulphate, proteinase 3, lactoferrin, collagenase, complement activator, complement receptor, N-formylmethionyl-leucyl-phenylalanine
(FMLP) receptor, laminin receptor, cytochrome b558, monocyte-chemotactic factor, histaminase, vitamin B12 binding protein, gelatinase, plasminogen activator, and a combination
thereof.
|